Roquefort Therapeutics plc (LON:ROQ – Get Free Report) shares traded up 10.2% on Thursday . The company traded as high as GBX 5.50 ($0.07) and last traded at GBX 4.47 ($0.06). 1,300,436 shares were traded during trading, an increase of 117% from the average session volume of 599,877 shares. The stock had previously closed at GBX 4.05 ($0.05).
Roquefort Therapeutics Stock Performance
The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The company has a market capitalization of £5.40 million, a PE ratio of -418.00 and a beta of 0.05. The firm’s 50-day simple moving average is GBX 4.33 and its 200-day simple moving average is GBX 4.14.
About Roquefort Therapeutics
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.
See Also
- Five stocks we like better than Roquefort Therapeutics
- What is a Secondary Public Offering? What Investors Need to Know
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Comparing and Trading High PE Ratio Stocks
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- What is a Low P/E Ratio and What Does it Tell Investors?
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
